Video
Author(s):
“What's novel about the iTind system is [that] it's one of the first treatments that [can] be deployed through a flexible cystoscope, as well as the fact that there is no permanent energy or permanent foreign body that's left within the prosthetic urethra,” says Bilal Chughtai, MD.
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
In this video, Bilal Chughtai, MD, discusses the advantages of the iTind system for patients with lower urinary tract symptoms (LUTS) secondary to BPH.
Chughtai also discusses the results of study he shared during the 2021 AUA Annual Meeting. The study was titled, “Preservation of ejaculatory and erectile function with iTind system for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia" (abstract MP01-06).
Chughtai is an associate professor of urology, obstetrics and gynecology at Weill Cornell Medicine and an attending urologist at NewYork-Presbyterian Hospital, New York City, New York.
Real-time IRP monitoring may redefine safety and scope of flexible ureteroscopy
Telehealth in urologic cancer: Lessons learned from the COVID-19 pandemic
Published data support safety, efficacy of vaginal insert for SUI
Enrollment progresses in study for cisplatin-induced hearing loss in testicular cancer
2 Commerce Drive
Cranbury, NJ 08512